GRPH Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (21 kov. 2024 @ 22:00):

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States...

Stats
Dzisiejszy wolumen	299 406
Średni wolumen	40 955.00
Kapitalizacja rynkowa	185.19M
EPS	$-0.400 ( 2024-03-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.207
ATR14	$0.0600 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-28	Drapkin Kimberlee C	Buy	40 000	Stock Option (right to buy)
2023-07-28	Drapkin Kimberlee C	Buy	0
2023-07-19	Viney Joanne L.	Buy	20 000	Stock Option (right to buy)
2023-07-19	Porteus Matthew	Buy	20 000	Stock Option (right to buy)
2023-07-19	Karsen Perry A	Buy	20 000	Stock Option (right to buy)

INSIDER POWER
100.00
Last 97 transactions
Buy: 36 276 632 \| Sell: 68 481 989

Wolumen Korelacja

Długi: 0.15 (neutral)

Krótki: 0.77 (moderate)

Signal:(51.506) Neutral

Graphite Bio, Inc. Korelacja

10 Najbardziej pozytywne korelacje
RAM	0.943
FAAR	0.941
MTEK	0.936
PRIM	0.936
IXAQ	0.934
EVER	0.934
GHRS	0.933
JUPW	0.933
NVAC	0.931
SVFAU	0.931

10 Najbardziej negatywne korelacje
DYNT	-0.95
FTFT	-0.949
INFI	-0.939
HCDIP	-0.938
DGLY	-0.935
HFFG	-0.929
BMRC	-0.928
CGRN	-0.927
CMLS	-0.927
APPS	-0.926

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Graphite Bio, Inc. Korelacja - Waluta/Towar

-0.63
( weak negative )

-0.67
( moderate negative )

0.12
( neutral )

-0.69
( moderate negative )

0.44
( neutral )

Graphite Bio, Inc. Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-2.41M (0.00 %)
EPS:	$-2.19

FY	2023
Przychody:	$0
Zysk brutto:	$-2.41M (0.00 %)
EPS:	$-2.19

FY	2022
Przychody:	$0
Zysk brutto:	$-8.35M (0.00 %)
EPS:	$-1.760

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-2.45

Financial Reports:

No articles found.

Graphite Bio, Inc.

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.